1.
Ibrahim AR, Clark RE, Holyoake TL, Byrne J, Shepherd P, Apperley JF, Milojkovic D, Szydlo R, Goldman J, Marin D. Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica 2011; 96(12):1779-1782; https://doi.org/10.3324/haematol.2011.049759.